You just read:

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

News provided by

I-Mab Biopharma

Jun 25, 2019, 10:01 ET